EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.

[powerpress]

An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.

[powerpress]

Progression-free survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate to increased overall survival?

[powerpress]

Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.

[powerpress]